文献速递核素与放射性配体治疗肿瘤 PET/CT

胃肠胰神经内分泌肿瘤且肝脏肿瘤负荷极高患者接受肽受体放射性核素治疗的肝毒性评估

Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden.
PubMed 文献 · J Nucl Med · 2023-04-20

该回顾性分析纳入371例接受至少1个周期177Lu-DOTATATE治疗的晚期胃肠胰神经内分泌肿瘤患者,其中15例在68Ga-DOTATATE PET/CT上肝脏受累超过75%并有增强腹部MRI或双期腹部CT资料;15例中1例出现不良事件通用术语标准5.0版定义的肝毒性,无3-5级肝毒性,作者认为PRRT对肝脏受累超过75%的患者可能是安全选择。

要点

  • 15例肝脏受累超过75%的患者中1例出现肝毒性(肝酶或胆红素恶化),无3-5级肝毒性。
  • 数据提示PRRT对肝脏受累超过75%的患者可能是安全选择。
  • 未来应研究不同肝脏受累程度患者的PRRT安全性。

核心结论

  • 作者认为,就疾病负荷所致肝损伤风险而言,数据提示PRRT对肝脏受累超过75%的患者可能是安全选择。
  • 未来应研究不同肝脏受累程度患者的PRRT安全性。

研究设计与样本

  • 回顾性分析371例在Mayo Clinic接受至少1个周期177Lu-DOTATATE治疗的晚期胃肠胰神经内分泌肿瘤患者。
  • 其中15例在68Ga-DOTATATE PET/CT上肝脏受累超过75%,并有增强腹部MRI或双期腹部CT检查。

主要发现

  • 15例肝脏受累超过75%的患者中,1例出现不良事件通用术语标准5.0版定义的肝毒性(肝酶或胆红素恶化)。
  • 无患者出现3-5级肝毒性(即肝功能衰竭的临床征象)。

关键数值与推荐

  • 肝毒性定义为不良事件通用术语标准5.0版所定义的肝酶或胆红素恶化。
  • 3-5级肝毒性定义为肝功能衰竭的临床征象。
  • 肝脏肿瘤负荷极高定义为肿瘤累及超过75%的肝脏。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of the current study was to describe the risk of hepatotoxicity for patients with gastroenteropancreatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy (PRRT) with a very high liver tumor burden, defined as tumor involving more than 75% of the liver. Methods: We conducted a retrospective analysis of 371 patients who received at least 1 cycle of 177Lu-DOTATATE at Mayo Clinic for advanced gastroenteropancreatic neuroendocrine tumors. We identified 15 total patients with more than 75% liver involvement on 68Ga-DOTATATE PET/CT and with either a contrast-enhanced abdominal MRI or dual-phase abdominal CT examination. Results: Of the 15 patients with more than 75% liver involvement, 1 experienced hepatotoxicity (i.e., worsening liver enzymes or bilirubin) as defined by the Common Terminology Criteria for Adverse Events, version 5.0. No patients had grade 3-5 hepatotoxicity (i.e., clinical signs of liver failure). Conclusion: When considering the risk of liver injury from PRRT due to burden of disease, our data suggest that PRRT may be a safe option in patients with more than 75% liver involvement. Future efforts should be made to determine the safety profile of PRRT in patients with varying degrees of liver involvement.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gococo-Benore DA, Kuhlman J, Parent EE, et al. Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden. J Nucl Med. 2023. PMID: 37080760. doi:10.2967/jnumed.122.264533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。